Vedanta Biosciences Publishes Seminal Research in Leading Scientific Journal Regarding its Immuno-oncology Candidate, VE800

Vedanta Biosciences Publishes Seminal Research in Leading Scientific Journal Regarding its Immuno-oncology Candidate, VE800

Source: 
CP Wire
snippet: 
  • The research demonstrates that specific, human microbiome-derived bacteria assembled rationally into consortia can cooperatively enhance the responses to immune checkpoint inhibitors
  • Based on this research, Vedanta is advancing VE800, a proprietary clinical candidate designed to enhance immune responses against cancer.
  • Vedanta plans to initiate clinical studies in 2019